CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a clinical study of CD19 / CD20 CAR-T cell infusion in the treatment of relapsed or
refractory hematological malignancies in CD19 / CD20 positive B cell lines.
The aim of this study was to evaluate the efficacy and safety of autologous chimeric antigen
receptor T cell infusion targeting CD19/CD20 in the treatment of relapsed or refractory CD19
/ CD20 positive B cell line hematological malignancies.